CTLA4 and breast carcinoma: Almost two decades ago, preclinical results from a model with poor immunogenic metastatic mouse mammary carcinoma demonstrated an increased survival when the CTLA-4 blockade was combined with RT, which correlated with the inhibition of lung metastases formation [160].